ArticlePharmaceuticals (Basel, Switzerland)2013
Antimicrobial peptides.
Article in Pharmaceuticals (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 538 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
538 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of carbapenemase genes in Klebsiella pneumoniae and Escherichia coli isolated from intensive care unit patients in Iran: a systematic review (2014-2025).Molecular biology reports · 2025Pooled it
- Revolutionizing orthopedic healthcare: a systematic review unveiling recombinant antimicrobial peptides.Frontiers in microbiology · 2024Pooled it
- Artificial intelligence catalyzes antimicrobial peptide design.Synthetic and systems biotechnology · 2027Review
- Membrane interactions and pore stability of aurein 1.2 and LLAA in single- and multi-peptide systems revealed by coarse-grained molecular dynamics simulations.Journal of molecular modeling · 2026Article
- Animal-Derived Antimicrobial Peptides: Emerging Therapeutic Strategies against Multidrug-Resistant Pathogens.Probiotics and antimicrobial proteins · 2026Review
- Protein Posttranslational Modifications in Immunity: Molecular Mechanisms and Therapeutic Targets.MedComm · 2026Review
- Antimicrobial Peptides as Eco-Innovative Therapeutics to Overcome Antifungal Pressure-Induced Resistance in Candida Infections.Current microbiology · 2026Review
- Development and Biological Evaluation of FL18-Based Novel Antimicrobial Peptide Constructs Against Bacterial Pathogens.ACS omega · 2026Article
- Article
- Antiviral efficacy of Trappin-2/Elafin against Zika virus in the human keratinocyte HaCaT cell line.Archives of virology · 2026Article
- Cooperative membrane association as a mechanistic origin of synergistic antimicrobial peptide activity.RSC chemical biology · 2026Review
- Antimicrobial Peptides, Bacteriocins and Mycocins as Natural Antimicrobials: Applications in Food Safety, Agriculture and Healthcare.Antibiotics (Basel, Switzerland) · 2026Review
- Broad-Spectrum Antiviral and Antibacterial Activity of the Scorpion Venom Peptide HP1090.Toxins · 2026Article
- Antimicrobial Peptides as Antibiotic Adjuvants: Overcoming Resistance through Multifaceted Mechanisms.Probiotics and antimicrobial proteins · 2026Article
- Exploring the Mechanism of Alyteserin-1c in Gram-Positive and Gram-Negative Bacterial Membrane Models Using a Computational Approach.MicrobiologyOpen · 2026Article
- A tri-modal contrastive learning framework for protein representation learning.Cell reports methods · 2026Article
- The Snakin Family of Antimicrobial Peptides: Promising Alternatives to Conventional Antibiotics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Efficacy and safety evaluation of artificial intelligence-identified antimicrobial peptides targeting avian pathogenic Escherichia coli in broiler chickens.Journal of animal science and biotechnology · 2026Article
- Peptides as a Therapeutic Alternative Against Leishmaniasis: A Scoping Review.Chemical biology & drug design · 2026Article
- Short Synthetic Lipopeptides CAntibiotics (Basel, Switzerland) · 2026Article
478 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid increase in drug-resistant infections has presented a serious challenge to antimicrobial therapies. The failure of the most potent antibiotics to kill "superbugs" emphasizes the urgent need to develop other control agents. Here we review the history and new development of antimicrobial peptides (AMPs), a growing class of natural and synthetic peptides with a wide spectrum of targets including viruses, bacteria, fungi, and parasites. We summarize the major types of AMPs, their modes of action, and the common mechanisms of AMP resistance. In addition, we discuss the principles for designing effective AMPs and the potential of using AMPs to control biofilms (multicellular structures of bacteria embedded in extracellular matrixes) and persister cells (dormant phenotypic variants of bacterial cells that are highly tolerant to antibiotics).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.